Skip to main content

If There's One Thing Preet Bharara Hates More Than Steve Cohen, It's Complex Carbohydrates

  • Author:
  • Updated:

What does one eat to get pumped up for a day of putting away gang members and bringing charges against (alleged!) financial dens of iniquity? Raw animal flesh or, if none can be procured, a granola bar that contains only 3g net carbs.

BusinessWeek: Could you describe a typical day in your job?

Bharara: It’s so varied. I joked once that a typical day could be like when, some months ago, in the morning we were finalizing a complaint against Bank of America. In the afternoon, assistants in this office were preparing to appear at the sentencing of Rajat Gupta. And in the evening we were putting the final touches on the complaint charging a police officer with conspiracy to kidnap, rape, and cannibalize.

BusinessWeek: So as far as your movements. You wake up …?

Bharara: My movements are a state secret, and I’m not allowed to tell you that. Other than to say I eat the same thing every day: raw meat.

BusinessWeek: Raw meat, OK.

Bharara: And when raw meat is unavailable, I eat a granola bar every morning and a Diet Coke.

BusinessWeek: Any particular type of granola bar?

Bharara: I eat a chocolate chip Atkins bar every morning. My children think it’s insane, because I don’t vary it. That can get me through the whole day almost.

U.S. Attorney Preet Bharara on Insider Trading, Cybercrime, and More [BusinessWeek]


If You Need Preet Bharara, He'll Be In His Office Screaming Into A Pillow

It's like the Supreme Court is trying to hurt him/discredit his life's work.

Preet Bharara: University Of Michigan Doctor Financially Compensated For Leaking Confidential Drug Trial Data To Former SAC Trader Just An Innocent Pawn In Big Bad Hedge Fund's Game

As you may have heard, earlier today, Mathew Martoma, a former portfolio manager in SAC Capital's CR Intrinsic unit, was charged with allegedly running “the most lucrative insider trading scheme ever," netting $276 million for the fund. He did so based on information that was given to him by Sid Gilman, a University of Michigan neurologist and chair of a "safety-monitoring committee that oversaw a clinical trial by Wyeth LLC and Elan Corp.  into whether the drug bapineuzumab, or bapi, was safe for patients with mild-to-moderate Alzheimer’s disease." Over an 18-month period, Gilman and Martoma met 42 times, in addition to emailing and chatting over the phone. For example: